BioSpace News Archive

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play IVD companies, today announced that through its continued partnership with the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Defense, the company been awarded an undefinitized contract which will lead to a $53.7 million contrac

MedMira Inc., reported on its financial results for the quarter ended January 31, 2021.

Following recent U.S. Food and Drug Administration actions to support test development, the FDA took swift action this week to get more tests for screening asymptomatic individuals on the market.

Quidel Corporation announced that it has received an Emergency Use Authorization from the U.S. FDA, allowing the company to market its new QuickVue® At-Home OTC COVID-19 Test for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two with at least 24 hours between tests.

Vesta, the leader in Community Powered Marketing, announced the launch of their new Applied Consumer Neuroscience suite of tools to seamlessly deliver deeper consumer intelligence from its online community software.

Maypro Industries’ Proprietary Branded Ingredients (PBI) division is proud to announce the publication of new research by Tokiwa Phytochemical (Tokiwa) and the University of Tokyo on a proprietary extract of Kaempferia parviflora (SIRTMAX®), commonly known as black turmeric.

Flagship project launched in partnership with Edmonton International Airport to keep front-line workers safe

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, provided additional information regarding the power calculation for the Phase 3 FOCUS trial of HEPZATO KIT in patients with liver dominant metastatic ocular melanoma.

Initial Acquisition in the Oncology Therapeutic Space for HLTT subsidiary, Healthtech Oncology, Inc. / Varian Biopharmaceuticals is Developing a Proprietary atypical Protein Kinase C iota Inhibitor in Multiple Formulations for A Broad Range of Tumor Types

RUBIX LS, a minority-led life science research firm focusing on solutions to support minorities within clinical trials, announced that it has formally launched its therapeutics division.